Emcure Pharmaceuticals announced leadership changes. Chairman Berjis Desai will retire post-AGM on September 21, 2026. MD & CEO Satish Mehta will become the new Chairman. Raghu Kumar appointed as Additional Independent Director.
Emcure Pharmaceuticals Board Leadership Transition
Emcure Pharmaceuticals Ltd. has announced significant changes to its board leadership. Mr. Berjis Desai will retire as Chairman and Non-Executive, Non-Independent Director following the company's Annual General Meeting (AGM) on September 21, 2026. Following this transition, Mr. Satish Mehta, the current Managing Director and CEO, will assume the role of Chairman from the conclusion of the same AGM.
New Independent Director Appointed
Further strengthening its board, Emcure Pharmaceuticals has appointed Mr. Raghu Kumar as an Additional Director (Non-Executive and Independent). This appointment is effective August 06, 2026, and is for a three-year term, pending shareholder approval at the upcoming AGM. Mr. Kumar brings a wealth of experience from senior leadership positions at global pharmaceutical and healthcare companies, including Allergan, Novartis, and Bayer. He currently serves as Chairman and Independent Director of Emcutix Biopharmaceuticals Limited, a subsidiary of Emcure.
Key Leadership Changes:
- Mr. Berjis Desai: Retiring Chairman, effective September 21, 2026.
- Mr. Satish Mehta: Moving from MD & CEO to Chairman, effective September 21, 2026.
- Mr. Raghu Kumar: Appointed as Additional Director, effective August 06, 2026.
Reader Takeaway: Continuity in founder leadership with Satish Mehta's Chairman role; enhanced oversight from new independent director.